9.25
+0.01 (+0.11%)
9.26
+0.01 (+0.11%)
ChartMill assigns a Buy % Consensus number of 60% to KIN. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 9.69. This target is 4.76% above the current price.
- KIN was analyzed by 5 analysts. The buy percentage consensus is at 60. So analysts seem to be rather neutral about KIN.
- In the last month the buy percentage fell by 8 points. So the trust of analysts is decreasing.
- Only 5 analysts analyzed KIN. So this is just the average opinion of a couple of analysts.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2021-06-17 | Lake Street | Downgrade | Buy -> Hold |
| 2021-06-17 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2021-06-16 | Aegis Capital | Downgrade | Buy -> Hold |
Kindred Biosciences / KIN FAQ
What do analysts expect the price target to be for Kindred Biosciences (KIN)?
5 analysts have analysed KIN and the average price target is 9.69 null. This implies a price increase of 4.76% is expected in the next year compared to the current price of 9.25.
Can you provide the consensus rating for Kindred Biosciences stock?
The consensus rating for Kindred Biosciences (KIN) is 60 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
How many analysts have analysed Kindred Biosciences (KIN)?
The number of analysts covering Kindred Biosciences (KIN) is 5.